Eli Lilly and Company $LLY Position Lessened by Cardinal Capital Management

Cardinal Capital Management trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 27,394 shares of the company’s stock after selling 604 shares during the quarter. Eli Lilly and Company accounts for about 3.9% of Cardinal Capital Management’s investment portfolio, making the stock its biggest position. Cardinal Capital Management’s holdings in Eli Lilly and Company were worth $29,440,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. DMKC Advisory Services LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $264,000. PVG Asset Management Corp increased its position in shares of Eli Lilly and Company by 25.9% during the fourth quarter. PVG Asset Management Corp now owns 466 shares of the company’s stock worth $501,000 after acquiring an additional 96 shares during the last quarter. Turning Point Benefit Group Inc. increased its position in shares of Eli Lilly and Company by 41.2% during the fourth quarter. Turning Point Benefit Group Inc. now owns 96 shares of the company’s stock worth $103,000 after acquiring an additional 28 shares during the last quarter. Smart Money Group LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $231,000. Finally, Ellenbecker Investment Group increased its position in shares of Eli Lilly and Company by 93.8% during the fourth quarter. Ellenbecker Investment Group now owns 779 shares of the company’s stock worth $838,000 after acquiring an additional 377 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Leerink Partners lowered their price objective on Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a report on Monday, April 27th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. TD Cowen boosted their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Finally, CICC Research boosted their price objective on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,212.96.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 results and guidance boost: Lilly reported roughly $19.8B revenue and $8.55 non‑GAAP EPS (well above consensus), raised 2026 revenue guidance to $82–85B and lifted EPS guidance to $35.50–37 — a primary driver of the rally. Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
• Positive Sentiment: Foundayo (oral GLP‑1) early traction: Foundayo — the first oral GLP‑1 with no food/water timing restrictions — has seen early prescriptions (management cites >20,000 patients), supporting longer‑term market share and convenience advantages versus rivals. Lilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
• Positive Sentiment: Regulatory tailwind for pricing/protection: The FDA proposed excluding key GLP‑1 active ingredients from the compounding bulk list — a move that would limit cheaper mass compounding and help protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Street upgrades and higher price targets: Major banks raised price targets and reiterated buy/overweight ratings after the results and guidance, supporting momentum from institutional analysts. Cantor Fitzgerald raises PT
• Neutral Sentiment: Novo’s oral rollout increases scrutiny: Novo Nordisk is expanding its oral GLP‑1 presence (rebranded Rybelsus/Ozempic pills across many pharmacies), a development investors will watch but which hasn’t flipped the narrative away from Lilly yet. Novo Launches Ozempic Pills Across 70,000 US Pharmacies
• Neutral Sentiment: Valuation and long‑term upside debate: Several analyses highlight a tension between Lilly’s strong top‑line growth and a stretched valuation after multi‑year gains; some see material upside if GLP‑1 momentum persists, others caution about multiple compression risk. Eli Lilly Stock’s Path To 30% Upside
• Negative Sentiment: Competitive and pricing pressure risks remain: PBM/insurer negotiation, faster ramps from rivals and longer‑term generic/compounding threats could pressure realized prices and margin expansion — a risk highlighted in market commentary despite the quarter’s beat. Fast Money panel on Novo vs Lilly
• Negative Sentiment: Regulatory / stakeholder friction: Hospital groups have pushed back on certain Lilly data/340B requests, which could create policy or reimbursement friction to monitor. AHA urges HHS to block Lilly 340B data demands

Eli Lilly and Company Stock Up 3.3%

Shares of Eli Lilly and Company stock opened at $965.19 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market cap of $911.93 billion, a P/E ratio of 34.29, a P/E/G ratio of 1.13 and a beta of 0.48. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The business has a 50-day moving average price of $947.05 and a 200 day moving average price of $986.14.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 115.33% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.